

Review

The role of tRNA-derived fragments in prostate cancer: a review

Shakur Babaei^{1,2}, Mehdi Khorrami^{2,3}, Amirhossein Eskandari⁴, Masoomah Ramazani^{1,2}, Ali Akbar Saffar Moghadam^{1,5*}, Mostafa Rezaei-Tavirani⁶, Shahrzad Soleimani⁷, Fatemeh Ghadyani⁸, Sepehr Kahrizi⁹, Abolfazl Movafagh^{8*}

¹ Department of Medical Genetics, School of Advanced Technologies in Medicine, Golestan University of Medical Sciences, Gorgan, Iran

² Student Research Committee, Golestan University of Medical Sciences, Gorgan, Iran

³ Department of Biochemistry, Golestan University of Medical Sciences, Gorgan, Iran

⁴ Deputy of Education, Ministry of Health, Tehran, Iran

⁵ Cancer Research Center, Golestan University of Medical Sciences, Gorgan, Iran

⁶ Proteomics Research Center, Faculty of Paramedical Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran

⁷ Department of Molecular Genetics, Institute of Basic Science, Shahrekord Islamic Azad University, Iran

⁸ Proteomics Research Center, Department of Medical Genetics, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran

⁹ Faculty of Medicine, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran

Article Info

Abstract



Article history:

Received: July 08, 2025

Accepted: September 12, 2025

Published: October 31, 2025

Use your device to scan and read the article online



Prostate Cancer (PCa) is a leading malignancy in men in developed countries. The lack of reliable prognostic markers in PCa hinders effective treatment, leading to potential patient misclassification and overtreatment with associated side effects. Recent advances in high-throughput sequencing have enabled the identification of tRNA-derived fragments (tRFs), small non-coding RNAs derived from tRNA cleavage. tRFs regulate crucial cellular processes like viability, differentiation, and homeostasis, implicating them in disease development, particularly cancer. Their potential as biomarkers for early diagnosis and prognosis, as well as targets for precision therapies, is increasingly recognized. This review focuses on the key biological functions of tRFs, including RNA silencing, translation regulation, and epigenetic regulation. It summarizes recent findings on tRFs in PCa, exploring their potential as clinical biomarkers and therapeutic targets.

Keywords: Prostate cancer; tRNA-derived fragments (tRFs); SHOT-RNAs; Non-coding RNA; Biomarker.

1. Introduction

Prostate cancer (PCa) is a leading cause of cancer and the second most common cause of cancer-related mortality in men [1]. This heterogeneous disease is influenced by genetic, environmental, and social factors, contributing to variable survival rates and epidemiology across different populations [2]. Affecting primarily men aged 45-60, PCa treatment is hindered by a lack of reliable biomarkers to predict disease outcomes [3]. This deficiency leads to potential overtreatment and associated side effects from surgery and radiation. While prostate-specific antigen (PSA) testing is used for diagnosis and prognosis, its limited specificity makes routine screening controversial, as it cannot effectively differentiate between benign condi-

tions and aggressive tumors. This highlights the need for improved diagnostic and prognostic tools [4]. Understanding the molecular mechanisms underlying PCa is crucial for identifying effective biomarkers and therapeutic strategies. Recent advances in high-throughput sequencing have revealed a new class of small noncoding RNAs: tRNA-derived fragments (tRFs) [5-7]. These 14-50 nucleotide fragments originate from precursor or mature tRNAs and participate in gene silencing, RNA processing, and protein translation, influencing cell stress response, growth, and differentiation [8, 9]. tRFs also play significant roles in various human diseases, including cancer [10]. tRFs have been classified into six categories according to their cleavage sites in the parental tRNA: 5'-tRFs, 3'-tRFs, 5'-tRNA

* Corresponding author.

E-mail address: saffarmoghadam@goums.ac.ir (A. A. S. Moghadam); movafagh.a@sbmu.ac.ir (A. Movafagh).

Doi: <http://dx.doi.org/10.14715/cmb/2025.71.10.13>

halves, 3'-tRNA halves, i-tRFs, and 3'-tRFs, also referred to as tsRNAs or 1-tRFs [11, 12]. tRFs are found widely across life. Initially considered tRNA degradation byproducts, their prevalence and consistent expression now suggest an important biological function [13-15]. This review explores the biogenesis, classification, and roles of tRFs, summarizing their presence and impact on prostate cancer as described in the current literature.

2. Classification and biogenesis of tRFs

tRNA-derived fragments (tRFs) are classified based on their origin within pre-tRNAs or mature tRNAs. Four main classes exist: 1-tRFs, generated by RNase Z (ELAC2) cleavage during pre-tRNA processing; [16, 17] 5'-tRFs, derived from the 5' end near the D-loop of mature tRNAs; 3'-tRFs, derived from the 3' end near the T ψ C loop; and i-tRFs, originating from internal tRNA sites [18]. tRNA halves, including 5'- and 3'-halves, are produced via angiogenin (ANG) cleavage at the anticodon loop and are also known as tRNA-derived stress-induced RNAs [19,20] (Figure 1). Aberrant tRF expression is implicated in cancer development and progression, affecting cell proliferation, metastasis, and overall malignancy [21]. Consequently, tRFs are promising biomarkers for cancer diagnosis, prognosis, and sub-typing.

3. tRF function

3.1. Regulation of transcription

Transcription is regulated by tRNA-derived small RNAs (tsRNAs). For example, Zhang *et al.* (2016) found that a tRNA-Glu-derived piRNA (td-piR(Glu)) interacts with PIWIL4 to recruit SETDB1, SUV39H1, and HP1 β to the CD1A promoter, promoting H3K9 methylation and suppressing CD1A transcription in human monocytes [23]. Similarly, sperm tRFs preferentially associate with promoter regions, potentially influencing metabolic trait inheritance and embryonic development [12]. tRFs, both Dicer-dependent and -independent, dynamically regulate processes during the transition from youth to adulthood. They interact with Argonaute proteins (AGOs) to form RNA-induced silencing complexes (RISCs), which bind to partially complementary regions, primarily within the 3' UTR of target mRNAs, resulting in translational repression and mRNA degradation [7, 24]. In Tetrahymena, 3'-tRF, along with 5'-tRF, associates with the PIWI protein Twi12 to activate the exonucleases Xrn2 and Tan1 for rRNA processing [25]. In Tetrahymena, 3'-tRF, along with 5'-tRF, associates with the PIWI protein Twi12 to activate the exonucleases Xrn2 and Tan1 for rRNA processing [26]. Furthermore, a set of i-tRFs originating from tRNAs like tRNA^{Glu}, tRNA^{Asp}, tRNA^{Gly}, and tRNA^{Tyr} disrupt YBX1 binding to the 3'UTRs of oncogenic transcripts in breast cancer cells, counteracting YBX1's stabilizing effect [27]. Finally, tGlnCTG interacts with IGF2BP1, an RNA-binding protein that stabilizes c-Myc mRNA, leading to decreased transcript stability and enhanced differentiation of mouse embryonic stem cells [28].

3.2. Regulation of translation

tRFs regulate global translation, acting as both positive and negative modulators. For example, ANG-induced 5'-tiRNAs, such as 5'-tiRNA^{Ala} and 5'-tiRNA^{Cys}, inhibit translation initiation by displacing the eIF4G/A/F complex from capped mRNA with the help of YB-1, promo-




Fig. 1. Classification and biogenesis of tRF [22]

ting stress granule formation [19]. Conversely, the Leu-CAG 3'-tRF enhances ribosome biogenesis by interacting with RPS28 and RPS15 mRNAs, increasing their translation and tumor cell viability [29]. Furthermore, the 5'-tRF Gln19 promotes translation elongation in HeLa cells by associating with the multi-syntetase complex (MSC); however, 5'-tRFs with a conserved GG-dinucleotide motif at their 3' ends can destabilize the MSC and inhibit ribosome maturation [30, 31].

3.3. In apoptosis

Beyond gene silencing and translation regulation, tRFs influence apoptosis. Hyperosmotic stress induces apoptosis in wild-type mouse embryonic fibroblasts by releasing cytochrome c from mitochondria and forming apoptosomes [32]. ANG treatment protects mouse embryonic fibroblasts (MEFs) and primary neurons from hypertonicity-induced apoptosis by generating 5'- and 3'-tiRNAs. These tiRNAs sequester cytosolic cytochrome c (Cyt c) into a ribonucleoprotein complex, limiting apoptosome formation and subsequent apoptosis [33].

3.4. Regulation of reverse transcription

Transposable elements (TEs) are mobile DNA segments whose transposition can disrupt genomic stability, leading to potentially harmful heterochromatin [34]. Consequently, TE transcription is often epigenetically regulated via DNA methylation and histone modifications. However, recent evidence suggests that tRNA-derived fragments (tRFs) also play a role in TE regulation. Specifically, 3'-tRFs inhibit mouse LTR-retrotransposons (ERVs) by competing with intact tRNAs for the primer binding site (PBS), thereby blocking reverse transcription. Conversely, tRF-3019 acts as a primer for the reverse transcriptase of human T cell leukemia virus type 1 (HTLV-1), enhancing viral infection [35, 36]. The 18-nucleotide 3'-tRNA fragments (3'-tRFs) specifically inhibit the activity of mouse LTR-retrotransposons, also known as endogenous retroviruses (ERVs), by competing with intact tRNAs for the highly conserved primer binding site (PBS) of these retrotransposons. This competition effectively blocks the reverse transcription process of the ERVs [36]. Another study indicates that tRF-3019 functions as a primer for the reverse transcriptase of human T cell leukemia virus type

1 (HTLV-1) by binding to the primer binding site (PBS), which subsequently enhances the viral infection process [37].

4. Role and clinical value of tRFs in cancers

MINTbase v2. 0, published in 2018, compiles 26, 531 unique human tRFs from TCGA data (as of October 2017) and serves as a resource for cancer-related tRF studies [38]. Correlation network analyses have revealed race and ethnicity-dependent associations between tRFs and mRNA in prostate adenocarcinoma and triple-negative breast cancer [39], highlighting the role of tRFs in posttranscriptional regulation in cancer. Aberrant tRF expression and function are observed across various cancers, including breast, gastric, and colorectal cancers, and correlate with clinical characteristics and survival outcomes [40, 41]. This analysis highlights the significant role of tRFs in posttranscriptional regulation related to cancer. It emphasizes that abnormal expression and function of specific tRFs are observed in various cancers, including breast, gastric, and colorectal cancers. Additionally, it points to a correlation between the dysregulation of tRFs and clinical characteristics as well as survival outcomes in cancer patients [42-44]. Overall, tRFs play a significant role in cancer development and progression, influencing key processes such as tumor cell proliferation, metastasis, apoptosis, and resistance to chemotherapy [21, 45, 46].

5. Type of tRFs in prostate cancer

5.1. tRF-1001

In 2009, Lee et al. identified tRF-1001, a tRF-1 derived from a Ser-TGA tRNA precursor, in a prostate cancer cell line using high-throughput RNA sequencing [7]. tRF-1001, a representative tRF-1 molecule, initiates immediately after the mature tRNA's 3' end, prior to CCA addition. The 3' ends of tRF-1 molecules are characterized by 5-6 consecutive thymines, indicative of RNA polymerase III termination sites [47]. These 3'-trailer sequences are generated during tRNA maturation by the tRNA endonuclease ELAC2[48]. ELAC2 knockdown reduces tRF-1001 levels while increasing pre-tRNA levels, confirming that tRF-1001 biogenesis occurs in the cytoplasm, where both molecules are exclusively localized [7]. tRF-1001 plays a significant role in cancer, especially in cell proliferation, and exhibits elevated expression in various cancer cell lines, correlating with cell growth. As a functional RNA fragment, tRF-1001 influences colon cancer cell proliferation by inducing G2 phase arrest. Given its cytoplasmic generation by ELAC2, a gene linked to prostate cancer susceptibility, tRFs like tRF-1001 are considered a distinct class of short RNAs with precise sequences and specific expression patterns, suggesting their potential as therapeutic targets or biomarkers for cancer diagnosis and prognosis [7, 49]. Studies indicate that tRF-1001 expression is dysregulated in prostate cancer tissues compared to normal tissues and correlates with clinical parameters like Gleason scores and progression-free survival [50, 51]. Elevated tRF-1001 levels in prostate cancer patients are associated with poorer prognoses, highlighting their potential as independent prognostic biomarkers for disease progression [46, 52]. The sequence of tRF-1001 is 5'-AAATAAGAGCACC-CGCTTC-3'.

5.2. tRF-Glu-TTC-2

tRF-Glu-TTC-2, a tRF-5c subtype generated from glutamic acid tRNA via cleavage by Dicer and angiogenin, is frequently detected in prostate cancer (PCa) tissues by RNA in situ hybridization. Quantitative RT-PCR analysis confirmed that tRF-Glu-TTC-2 expression is significantly elevated in PCa tissues compared to normal adjacent tissues, indicating its potential oncogenic role in PCa initiation and progression. High expression levels of tRF-Glu-TTC-2 correlate closely with tumor size and Gleason score, and functional studies demonstrate that its overexpression promotes PCa cell proliferation, while knockdown suppresses tumor growth both in vitro and in vivo. These findings suggest that tRF-Glu-TTC-2 acts as a novel oncogene driving PCa growth and may serve as a promising molecular marker for diagnosis and a potential therapeutic target in prostate cancer management. Its association with increased tumor cell proliferation indicates that tRF-Glu-TTC-2 may be a cancer-promoting gene linked to PCa progression and prognosis. Targeting tRF-Glu-TTC-2 (sequence: 5-TCGACTCCCGGTATGGGAAC-CA-3) [53]. Represents a potential therapeutic strategy to slow tumor growth and improve PCa treatment effectiveness, warranting further investigation of its mechanisms and therapeutic potential.

5.3. tRF -315, tRF -544

tRF-315 and tRF-544, two tRNA-derived fragments (tRFs), exhibit contrasting expression patterns in prostate cancer and are implicated in cancer biology. tRF-315, derived from tRNA(Lys)-CTT (5-CCCGGCTAGCTCAGTC-GGTAGAGCATGG -3) and typically 18-22 nucleotides long, is often upregulated in cancer tissues. Conversely, tRF-544, derived from tRNA(Phe)-GAA (5-TCCCTGG TTCGATCCCGGGTTTCGGCA-3) and typically 14-30 nucleotides long, is usually downregulated [55, 56]. The tRF-315/tRF-544 ratio shows promise as a biomarker for prostate cancer progression; a higher ratio correlates with poorer progression-free survival and shorter time to relapse, suggesting that monitoring these levels could inform patient outcomes [55, 57].

Both tRFs influence cellular processes, including gene regulation and stress response. tRF-315 interacts with oncogenic proteins, potentially impacting tumor growth and metastasis [55, 58], and prevents apoptosis in prostate cancer cells, particularly in response to cisplatin, by targeting genes like GADD45A. Differential expression suggests their regulatory roles in tumor biology, modulating gene expression and oncogenic transcript stability, crucial for cancer development [59, 60]. Research has shown that tRF-544 is downregulated in prostate cancer tissues compared to healthy tissues. The ratio of tRF-544 has been identified as a potential biomarker for prostate cancer progression. A higher ratio correlates suggesting that monitoring this ratio could aid in assessing tumor aggressiveness and guiding treatment strategies [18, 54]. Knockdown experiments show that reducing tRF-315 inhibits prostate cancer cell proliferation, indicating its oncogenic role. Given its involvement in tumor progression and treatment response, tRF-315 is being explored as a potential therapeutic target to improve cancer treatment [54, 57, 61].

5.4. tRF-562

Prostate cancer RNA sequencing reveals significant

deregulation of tRNA-derived fragments (tRFs), including tRF 562 (5-TCGATTCCCGGCCAACGC-3), compared to normal tissue. This differential expression, with both up- and downregulation, suggests a role for tRFs in tumor biology [50].

5. 5. SHOT-RNAs

Sex hormone-dependent tRNA-derived RNAs (SHOT-RNAs), a newly discovered class of tRNA-derived small RNAs, are produced through angiogenin (ANG)-mediated cleavage of aminoacylated mature tRNAs at the anticodon loop [62]. Similar to tRNA-derived stress-induced RNAs (tiRNAs), which also result from ANG-mediated cleavage under stress conditions [62, 63].

SHOT-RNAs are particularly expressed in sex hormone-dependent cancers. In these cancers, where sex hormones and their receptors are crucial for development and progression, SHOT-RNAs influence sex hormone signaling, stimulating ANG-mediated tRNA cleavage and generating two types: 5'-SHOT-RNAs (5'-phosphate, 3'-cyclic phosphate) and 3'-SHOT-RNAs (5'-hydroxyl, 3'-amino acid). Notably, 5'-SHOT-RNAs promote cell proliferation [64]. SHOT-RNAs are significantly expressed in estrogen receptor-positive breast cancer and androgen receptor-positive prostate cancer but not in other cancer types or receptor-negative counterparts [54, 64] suggesting specific regulation by sex hormones. Their distinct expression pattern makes SHOT-RNAs potential biomarkers for diagnosing and monitoring hormone-dependent cancers, reflecting potential tumor behavior and patient prognosis.

6. Methods

This review was conducted through a systematic literature search using databases such as PubMed, Google Scholar, Web of Science, and ScienceDirect, focusing on peer-reviewed articles (2010–2024) related to tRNA-de-

rived fragments (tRFs) and their role in prostate cancer (PCa). Key search terms included "tRNA-derived fragments," "tRFs," "prostate cancer," "SHOT-RNAs," and "non-coding RNA biomarkers." Relevant studies were selected based on their focus on tRF biogenesis, classification, molecular functions, and clinical implications in PCa, while non-English and irrelevant publications were excluded. Data extraction centered on the mechanisms of tRF action, including their roles in transcription, translation, apoptosis, and retrotransposon regulation, with particular emphasis on well-characterized tRFs such as tRF-1001, tRF-Glu-TTC-2, tRF-315, tRF-544, tRF-562, and SHOT-RNAs. Bioinformatics resources, including MINTbase v2.0 and TCGA datasets, were utilized to analyze tRF expression profiles in PCa. Additionally, experimental evidence from knockdown studies, qRT-PCR, and RNA-seq was evaluated to assess tRF interactions with key proteins (e.g., YBX1, IGF2BP1, angiogenin) and their impact on cancer progression. Clinical correlations, such as associations with Gleason scores, progression-free survival, and therapeutic resistance, were also examined to explore the diagnostic, prognostic, and therapeutic potential of tRFs in PCa. This comprehensive approach ensured a thorough synthesis of current knowledge on tRFs in prostate cancer.

7. Conclusion and suggestion

The study identifies a new class of small non-coding RNAs, known as tRNA-derived fragments (tRFs), as potential clinical biomarkers for diagnosing, prognosing, and classifying tumors in prostate cancer (PCa) patients. This article suggests that tRFs can offer important diagnostic and prognostic insights that are independent of the Gleason score, potentially aiding clinicians in developing improved treatment strategies. Further investigation into these dysregulated tRFs is expected to uncover new mechanisms related to the development and progression

Table1. Summarize various tRNA-derived fragments (tRFs) in prostate cancer.

Name	Sequence	Origin	Role / Implication in cancer
tRF-1001	5'-AAATAAGAGCACCCGCTTC-3'	Derived from Ser-TGA tRNA precursor	Elevated in cancer; induces G2 arrest; associated with prognosis
tRF-Glu-TTC-2	5-TCGACTCCCGGTATGGGAACCA-3'	Derived from glutamic acid tRNA	Elevated in prostate cancer; promotes proliferation; potential therapeutic target
tRF-315	(5-CCCGGCTAGCTCAGTCGGTAGAGCATGG -3)	Derived from tRNA(Lys)-CTT	Upregulated in cancer tissues, tRF-315 promotes tumor growth; inhibits apoptosis; knockdown reduces proliferation
tRF-544	(5-TCCCTGGTTCGATCCCGGGTTTCGGCA-3)	Derived from tRNA(Phe)-GAA	Downregulated in prostate cancer tissues, Higher tRF-315/tRF-544 ratio linked to poor prognosis
tRF-562	5-TCGATTCCCGGCCAACGC-3'	Derived from tRN -GLy	Deregulated in prostate cancer tissue, may play role in tumor biology; both up/down regulated
SHOT-RNAs	Derived via angiogenin cleavage; 5'-SHOT and 3'-SHOT	From mature tRNAs at anticodon loop, hormone-dependent expression	Promote cell proliferation; potential biomarkers in hormone-dependent cancers

of PCa. Although tRFs show great promise as diagnostic, prognostic, and therapeutic targets in cancer, several limitations must be addressed for their clinical application. A key limitation is the intra- and inter-heterogeneity of tRF expression, which complicates the identification of universal tRF biomarkers for cancer diagnosis and prognosis. Additionally, the unclear molecular mechanisms underlying the dysregulation of tRF expression in cancer further hinder their clinical use. The advancement of tRF-based therapies also encounters challenges, including the effective delivery of therapeutic tRFs to targeted cells and tissues and the risk of off-target effects that could impact normal cellular functions. There is a need for more research to establish safe and effective delivery methods for therapeutic tRFs and to assess their potential toxicity and side effects. Furthermore, the limited understanding of the range of tRF functions and regulatory mechanisms in biological processes impedes the development of targeted tRF-based therapies. The intricate nature of tRF-mediated regulatory networks and their interactions with other regulatory molecules and pathways necessitates further exploration to fully realize the potential of tRFs in cancer diagnosis and treatment.

Acknowledgements

Not applicable

Statements and declarations

Authors' contributions

All authors declare equal contribution to the preparation of the current manuscript. AASM and AM supervised the writing, analyses, and revision of the manuscript. All authors read and approved the final manuscript.

Funding

The authors declare that no funds, grants, or other support were received during the preparation of this manuscript.

Consent for publication

All authors agree to submit the manuscript for publications.

Conflict of interest

The authors declare no competing interests.

Availability of data and material

Not applicable

Use of Artificial Intelligence Tools

Some sentences in this manuscript were revised using artificial intelligence language models to enhance clarity and readability. All final content decisions and intellectual contributions remain solely the responsibility of the authors.

References

1. Carlsson S, Vickers AJ, Roobol M (2012) Prostate cancer screening: facts, statistics, and interpretation in response to the US Preventive Services Task Force Review. *J Clin Oncol* 30(21):2581-2584. doi:10.1200/JCO.2011.40.4327
2. Hjelmborg JB, Scheike T, Holst K (2014) The heritability of prostate cancer in the Nordic Twin Study of Cancer. *Cancer Epidemiol Biomarkers Prev* 23(11):2303-2310. doi:10.1158/1055-9965.EPI-13-0568
3. Chen J, Zhang D, Yan W, Yang D, Shen B (2013) Translational bioinformatics for diagnostic and prognostic prediction of prostate cancer in the next-generation sequencing era. *Biomed Res Int* 2013:901578. doi:10.1155/2013/901578
4. Nam RK, Cheung P, Herschorn S (2014) Incidence of complications other than urinary incontinence or erectile dysfunction after radical prostatectomy or radiotherapy for prostate cancer: a population-based cohort study. *Lancet Oncol* 15(2):223-231. doi:10.1016/S1470-2045(13)70606-5
5. Kawaji H, Nakamura M, Takahashi Y (2008) Hidden layers of human small RNAs. *BMC Genomics*. 2008;9:157. Published 2008 Apr 10. doi:10.1186/1471-2164-9-157
6. Cole C, Sobala A, Lu C (2009) Filtering of deep sequencing data reveals the existence of abundant Dicer-dependent small RNAs derived from tRNAs. *RNA* 15(12):2147-60. doi:10.1261/rna.1738409
7. Lee YS, Shibata Y, Malhotra A, Dutta A (2009) A novel class of small RNAs: tRNA-derived RNA fragments (tRFs). *Genes Dev* 23(22):2639-2649. doi:10.1101/gad.1837609
8. Anastasiadou E, Jacob LS, Slack FJ (2018) Non-coding RNA networks in cancer. *Nat Rev Cancer* 18(1):5-18. doi:10.1038/nrc.2017.2099
9. Kumar P, Kuscu C, Dutta A (2016) Biogenesis and Function of Transfer RNA-Related Fragments (tRFs). *Trends Biochem Sci* 41(8):679-689. doi:10.1016/j.tibs.2016.05.004
10. Sun C, Fu Z, Wang S (2018) Roles of tRNA-derived fragments in human cancers. *Cancer Lett* 414:16-25. doi:10.1016/j.canlet.2017.10.031
11. Zimbauer R, Ammon D, Renner A, Hartman N, Kalinina P, Starlinger P et al (2025) Differential prognostic roles and clinical implications of mitochondrial and genomic tRNA-derived fragments in colorectal liver metastases. *J Transl Med* 12;23(1):786. doi:10.1186/s12967-025-06850-3.
12. Yu M, Lu B, Zhang J, Ding J, Liu P, Lu Y (2020) tRNA-derived RNA fragments in cancer: current status and future perspectives. *J Hematol Oncol* 13(1):121. Published 2020 Sep 4. doi:10.1186/s13045-020-00955-6
13. Kumar P, Anaya J, Mudunuri SB, Dutta A (2014) Meta-analysis of tRNA derived RNA fragments reveals that they are evolutionarily conserved and associate with AGO proteins to recognize specific RNA targets. *BMC Biol* 12:78. Published 2014 Oct 1. doi:10.1186/s12915-014-0078-0
14. Martens-Uzunova ES, Olvedy M, Jenster G (2013) Beyond microRNA--novel RNAs derived from small non-coding RNA and their implication in cancer. *Cancer Lett* 340(2):201-211. doi:10.1016/j.canlet.2012.11.058
15. Thompson DM, Parker R (2009) Stressing out over tRNA cleavage. *Cell* 138(2):215-219. doi:10.1016/j.cell.2009.07.001
16. Phizicky EM, Hopper AK (2010) tRNA biology charges to the front. *Genes Dev* 24(17):1832-1860. doi:10.1101/gad.1956510
17. Gebetsberger J, Polacek N (2013) Slicing tRNAs to boost functional ncRNA diversity. *RNA Biol* 10(12):1798-1806. doi:10.4161/rna.27177
18. Sun C, Fu Z, Wang S (2018) Roles of tRNA-derived fragments in human cancers. *Cancer Lett* 414:16-25. doi:10.1016/j.canlet.2017.10.031
19. Li S, Shi X, Chen M (2019) Angiogenin promotes colorectal cancer metastasis via tRNA production. *Int J Cancer* 145(5):1395-1407. doi:10.1002/ijc.32245
20. Yamasaki S, Ivanov P, Hu GF, Anderson P (2009) Angiogenin cleaves tRNA and promotes stress-induced translational repression. *J Cell Biol* 185(1):35-42. doi:10.1083/jcb.200811106
21. Sun X, Yang J, Yu M (2020) Global identification and characteri-

- zation of tRNA-derived RNA fragment landscapes across human cancers. *NAR Cancer* 2(4):zcaa031. Published 2020 Oct 19. doi:10.1093/narcan/zcaa031
22. Li N, Yao S, Yu G, Lu L, Wang Z (2024) tRFtarget 2. 0: expanding the targetome landscape of transfer RNA-derived fragments. *Nucleic Acids Res* 52(D1):D345-D350. doi:10.1093/nar/gkad815
 23. Zhang X, He X, Liu C (2016) IL-4 Inhibits the Biogenesis of an Epigenetically Suppressive PIWI-Interacting RNA To Upregulate CD1a Molecules on Monocytes/Dendritic Cells. *J Immunol* 196(4):1591-1603. doi:10.4049/jimmunol.1500805
 24. Kuscic C, Kumar P, Kiran M, Su Z, Malik A, Dutta A (2018) tRNA fragments (tRFs) guide Ago to regulate gene expression post-transcriptionally in a Dicer-independent manner. *RNA* 24(8):1093-1105. doi:10.1261/rna.066126.118
 25. Couvillion MT, Bounova G, Purdom E, Speed TP, Collins K (2012) A Tetrahymena Piwi bound to mature tRNA 3' fragments activates the exonuclease Xrn2 for RNA processing in the nucleus. *Mol Cell* 48(4):509-520. doi:10.1016/j.molcel.2012.09.010
 26. Balatti V, Nigita G, Veneziano D (2017) tsRNA signatures in cancer. *Proc Natl Acad Sci U S A* 114(30):8071-8076. doi:10.1073/pnas.1706908114
 27. Goodarzi H, Liu X, Nguyen HC, Zhang S, Fish L, Tavazoie SF (2015) Endogenous tRNA-Derived Fragments Suppress Breast Cancer Progression via YBX1 Displacement. *Cell* 161(4):790-802. doi:10.1016/j.cell.2015.02.053
 28. Krishna S, Yim DG, Lakshmanan V (2019) Dynamic expression of tRNA-derived small RNAs define cellular states. *EMBO Rep* 20(7):e47789. doi:10.15252/embr.201947789
 29. Kim HK, Fuchs G, Wang S (2017) A transfer-RNA-derived small RNA regulates ribosome biogenesis. *Nature* 552(7683):57-62. doi:10.1038/nature25005
 30. Sobala A, Hutvagner G (2013) Small RNAs derived from the 5' end of tRNA can inhibit protein translation in human cells. *RNA Biol* 10(4):553-563. doi:10.4161/rna.24285
 31. Keam SP, Sobala A, Ten Have S, Hutvagner G (2017) tRNA-Derived RNA Fragments Associate with Human Multisynthetase Complex (MSC) and Modulate Ribosomal Protein Translation. *J Proteome Res* 16(2):413-420. doi:10.1021/acs.jproteome.6b00267
 32. Bevilacqua E, Wang X, Majumder M (2010) eIF2alpha phosphorylation tips the balance to apoptosis during osmotic stress. *J Biol Chem* 285(22):17098-17111. doi:10.1074/jbc.M110.109439
 33. Saikia M, Jobava R, Parisien M (2014) Angiogenin-cleaved tRNA halves interact with cytochrome c, protecting cells from apoptosis during osmotic stress. *Mol Cell Biol* 34(13):2450-2463. doi:10.1128/MCB.00136-14
 34. Slotkin RK, Martienssen R. (2007) Transposable elements and the epigenetic regulation of the genome. *Nat Rev Genet* 8(4):272-285. doi:10.1038/nrg2072
 35. Martinez G, Choudury SG, Slotkin RK (2017) tRNA-derived small RNAs target transposable element transcripts. *Nucleic Acids Res* 45(9):5142-5152. doi:10.1093/nar/gkx103
 36. Schorn AJ, Gutbrod MJ, LeBlanc C, Martienssen R (2017) LTR-Retrotransposon Control by tRNA-Derived Small RNAs. *Cell* 170(1):61-71. e11. doi:10.1016/j.cell.2017.06.013
 37. Ruggero K, Guffanti A, Corradin A (2014) Small noncoding RNAs in cells transformed by human T-cell leukemia virus type 1: a role for a tRNA fragment as a primer for reverse transcriptase. *J Virol* 88(7):3612-3622. doi:10.1128/JVI.02823-13
 38. Pliatsika V, Loher P, Magee R (2018) MINTbase v2. 0: a comprehensive database for tRNA-derived fragments that includes nuclear and mitochondrial fragments from all The Cancer Genome Atlas projects. *Nucleic Acids Res* 46(D1):D152-D159. doi:10.1093/nar/gkx1075
 39. da Silva HB, Amaral EP, Nolasco EL (2013) Dissecting Major Signaling Pathways throughout the Development of Prostate Cancer. *Prostate Cancer* 2013:920612. doi:10.1155/2013/920612
 40. Magee RG, Telonis AG, Loher P, Londin E, Rigoutsos I (2018) Profiles of miRNA Isoforms and tRNA Fragments in Prostate Cancer. *Sci Rep* 8(1):5314. Published 2018 Mar 28. doi:10.1038/s41598-018-22488-2
 41. Telonis AG, Rigoutsos I (2018) Race Disparities in the Contribution of miRNA Isoforms and tRNA-Derived Fragments to Triple-Negative Breast Cancer. *Cancer Res* 78(5):1140-1154. doi:10.1158/0008-5472.CAN-17-1947
 42. Wang J, Ma G, Ge H (2021) Circulating tRNA-derived small RNAs (tsRNAs) signature for the diagnosis and prognosis of breast cancer. *NPJ Breast Cancer* 7(1):4. Published 2021 Jan 5. doi:10.1038/s41523-020-00211-7
 43. Yang Y, Guo JX, Shao ZQ (2016) miR-21 targets and inhibits tumor suppressor gene PTEN to promote prostate cancer cell proliferation and invasion: An experimental study. *Asian Pac J Trop Med* 10(1):87-91. doi:10.1016/j.apjtm.2016.09.011
 44. Xi J, Zeng Z, Li X, Zhang X, Xu J (2021) Expression and Diagnostic Value of tRNA-Derived Fragments Secreted by Extracellular Vesicles in Hypopharyngeal Carcinoma. *Onco Targets Ther* 2021;14:4189-4199. Published 14. doi:10.2147/OTT.S320176
 45. Luan N, Mu Y, Mu J (2021) Dicer1 Promotes Colon Cancer Cell Invasion and Migration Through Modulation of tRF-20-MEJ-B5Y13 Expression Under Hypoxia. *Front Genet* 2021;12:638244. Published 8. doi:10.3389/fgene.2021.638244
 46. Xu C, Liang T, Zhang F, Liu J, Fu Y (2021) tRNA-derived fragments as novel potential biomarkers for relapsed/refractory multiple myeloma. *BMC Bioinformatics* 2021;22(1):238. Published 11. doi:10.1186/s12859-021-04167-8
 47. Koski RA, Clarkson SG (1982) Synthesis and maturation of *Xenopus laevis* methionine tRNA gene transcripts in homologous cell-free extracts. *J Biol Chem* 257(8):4514-4521
 48. Takaku H, Minagawa A, Takagi M, Nashimoto M (2003) A candidate prostate cancer susceptibility gene encodes tRNA 3' processing endoribonuclease. *Nucleic Acids Res* 31(9):2272-2278. doi:10.1093/nar/gkg337
 49. Fu M, Gu J, Wang M (2023) Emerging roles of tRNA-derived fragments in cancer. *Mol Cancer* 2023;22(1):30. Published 13. doi:10.1186/s12943-023-01739-5
 50. Olvedy M, Scaravilli M, Hoogstrate Y, Visakorpi T, Jenster G, Martens-Uzunova ES (2016) A comprehensive repertoire of tRNA-derived fragments in prostate cancer. *Oncotarget* 7(17):24766-24777. doi:10.18632/oncotarget.8293
 51. Pekarsky Y, Balatti V, Croce CM (2023) tRNA-derived fragments (tRFs) in cancer. *J Cell Commun Signal* 17(1):47-54. doi:10.1007/s12079-022-00690-2
 52. Jiang Q, Ma Y, Zhao Y (2022) tRNA-derived fragment tRF-1001: A novel anti-angiogenic factor in pathological ocular angiogenesis. *Mol Ther Nucleic Acids* 30:407-420. Published 2022 Oct 31. doi:10.1016/j.omtn.2022.10.016
 53. Wang L, Liu Y, Yan W (2022) Clinical Significance of High Expression of tRF-Glu-TTC-2 in Prostate Carcinoma and its Effect on Growth. *Am J Mens Health* 16(6):15579883221135970. doi:10.1177/15579883221135970
 54. Mao C, Yuan W, Fang R, Wu Y, Zhang Z, Cong H (2024) Transfer RNA derived small RNAs: A class of potential biomarkers in multiple cancers (Review). *Oncol Lett* 28(1):293. Published 2024 May 1. doi:10.3892/ol.2024.14427
 55. Jia Y, Tan W, Zhou Y (2020) Transfer RNA-derived small RNAs: potential applications as novel biomarkers for disease diagnosis and prognosis. *Ann Transl Med* 8(17):1092. doi:10.21037/atm-20-2797

56. Zhang Y, Qian H, He J, Gao W (2020) Mechanisms of tRNA-derived fragments and tRNA halves in cancer treatment resistance. *Biomark Res* 8:52. Published 2020 Oct 15. doi:10. 1186/s40364-020-00233-0
57. Mao M, Chen W, Huang X, Ye D (2023) Role of tRNA-derived small RNAs(tsRNAs) in the diagnosis and treatment of malignant tumours. *Cell Commun Signal*. 2023;21(1):178. Published 21. doi:10. 1186/s12964-023-01199-w
58. Chu X, He C, Sang B (2022) Transfer RNAs-derived small RNAs and their application potential in multiple diseases. *Front Cell Dev Biol* 10:954431. Published 2022 Aug 22. doi:10. 3389/fcell. 2022. 954431
59. Yu X, Xie Y, Zhang S, Song X, Xiao B, Yan Z (2021) tRNA-derived fragments: Mechanisms underlying their regulation of gene expression and potential applications as therapeutic targets in cancers and virus infections. *Theranostics* 11(1):461-469. Published 2021 Jan 1. doi:10. 7150/thno. 51963
60. Cabrelle C, Giorgi FM, Mercatelli D (2024) Quantitative and qualitative detection of tRNAs, tRNA halves and tRFs in human cancer samples: Molecular grounds for biomarker development and clinical perspectives. *Gene* 898:148097. doi:10. 1016/j. gene. 2023. 148097
61. Gong M, Deng Y, Xiang Y, Ye D (2023) The role and mechanism of action of tRNA-derived fragments in the diagnosis and treatment of malignant tumors. *Cell Commun Signal* 21(1):62. Published 2023 Mar 24. doi:10. 1186/s12964-023-01079-3
62. Honda S, Loher P, Shigematsu M (2015) Sex hormone-dependent tRNA halves enhance cell proliferation in breast and prostate cancers. *Proc Natl Acad Sci U S A* 112(29):E3816-E3825. doi:10. 1073/pnas. 1510077112
63. Shigematsu M, Honda S, Kirino Y (2024) Transfer RNA as a source of small functional RNA. *J Mol Biol Mol Imaging* 1(2):8.
64. Honda S, Kirino Y (2015) SHOT-RNAs: A novel class of tRNA-derived functional RNAs expressed in hormone-dependent cancers. *Mol Cell Oncol* 3(2):e1079672. Published 2015 Nov 23. doi:10. 1080/23723556. 2015. 1079672